Explore Luminary’s pipeline
Unlocking Access: Solving Cost and Centralized Manufacturing Barriers in Cell Therapy to overcome autoimmune disorders and hard to treat cancers
Our product pipeline focuses on autoimmune disorders and solid tumors. We are aggressively applying our BAFF CAR to autoimmune disorders and multiple dual targeting CAR optimization designs towards breaking down the barriers of CAR T in the treatments of solid tumors.
We believe our allogeneic platform will fundamentally change access and affordability of CAR T therapies. Here’s our progress towards making that a reality.
| Program | Status | Cell Type | Product | Discovery / Pre-Clinical | Phase I | Phase II | Phase III | Patients Treated |
|---|---|---|---|---|---|---|---|---|
| BAFF-CAR | Active / Enrolling | αβ T cell | LMY-920 | Non-Hodgkin Lymphoma (NHL) | 5 | |||
| Multiple Myeloma (MM) | 2 | |||||||
| Chronic Lymphocytic Leukemia (CLL) | 1 | |||||||
| Lupus | Soon | |||||||
| Upcoming 2025/2026 | γδ T cell | LMY-922 | Rheumatoid Arthritis | |||||
| Chronic Lymphocytic Leukemia (CLL) | ||||||||
| Split Co-Stim Dual CAR | Upcoming 2025/2026 | γδ T cell | LMY-232 | Renal Carcinoma / Esophageal | ||||
| LMY-252 | Lung / Colorectal | |||||||
| Future Development Work | γδ T cell | LMY-272 | Osteosarcoma |
![](https://www.luminarytx.com/wp-content/uploads/us.png")